TREVENA, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-12-21: Form 8-K; Period of report 2018-12-18; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2018-11-08: Form 8-K; Period of report 2018-11-08; Description 2.02 Results of Operations and Financial Condition; 2.05 Costs Associated with Exit or Disposal Activities; 8.01 Other Events; Details 2.02.
- 2018-11-02: Form 8-K; Period of report 2018-11-02; Description 8.01 Other Events; Details 8.01.
- 2018-10-17: Form 8-K; Period of report 2018-10-11; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-12-21 | 8-K | 2018-12-18 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On December 18, 2018, Trevena, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share required for continued inclusion on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Notice”). | a18-41868_18k.htm |
| 2018-11-08 | 8-K | 2018-11-08 | 2.02 Results of Operations and Financial Condition; 2.05 Costs Associated with Exit or Disposal Activities; 8.01 Other Events | 2.02 The information under this caption and contained in the press release attached hereto as Exhibit 99.1 is furnished by Trevena, Inc. (the “Company”) in accordance with Securities Exchange Commission Release No. 33-8216. 2.05 On November 8, 2018, management of the Registrant, upon the approval of the Board of Directors of the Company, announced a workforce restructuring (the “Restructuring”) of approximately one-third of its workforce, or 14 employees, intended to lower the Registrant’s annualized net operating cash burn. 8.01 On November 8, 2018, the Company issued a press release announcing financial results for the quarter ended September 30, 2018 and the Restructuring. | a18-39773_18k.htm |
| 2018-11-02 | 8-K | 2018-11-02 | 8.01 Other Events | 8.01 On November 2, 2018, the Company issued a press release announcing that the U.S. Food and Drug Administration has issued a complete response letter with respect to the Company’s New Drug Application for oliceridine. | a18-39511_18k.htm |
| 2018-10-17 | 8-K | 2018-10-11 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a18-36837_18k.htm |
| 2018-10-12 | 8-K | 2018-10-11 | 8.01 Other Events | 8.01 On October 11, 2018, Trevena, Inc. (the “Company”) issued a press release announcing the outcome of the meeting of the U.S. Food and Drug Administration Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) to review and discuss the Company’s lead investigational product, oliceridine. | a18-36145_28k.htm |
| 2018-10-11 | 8-K | 2018-10-11 | 7.01 Regulation FD Disclosure | 7.01 Trevena, Inc. (the “Company” or the “Sponsor”) is providing the following information to clarify and further expand upon the interactions between Trevena and the U.S. Food and Drug Administration (“FDA”) with respect to the primary endpoint for the two pivotal Phase 3 studies, APOLLO-1 and APOLLO-2, conducted by the Company with respect to oliceridine. | a18-36145_38k.htm |
| 2018-10-01 | 8-K | 2018-09-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) As previously announced by Trevena, Inc. (the “Company”), Maxine Gowen, Ph.D., retired as the Company’s President and Chief Executive Officer, effective as of October 1, 2018. | a18-36145_18k.htm |
| 2018-08-02 | 8-K | 2018-08-02 | 2.02 Results of Operations and Financial Condition | 2.02 The information under this caption and contained in the press release attached hereto as Exhibit 99.1 is furnished by Trevena, Inc. (the “Company”) in accordance with Securities Exchange Commission Release No. 33-8216. | a18-18137_18k.htm |
| 2018-06-15 | 8-K | 2018-06-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a18-15138_38k.htm |
| 2018-06-13 | 8-K | 2018-06-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (c) On June 11, 2018, the Board of Directors of Trevena, Inc. (the “Company”) appointed John P. Hamill as the Company’s interim Principal Financial Officer and Principal Accounting Officer. | a18-15138_28k.htm |
| 2018-05-21 | 8-K | 2018-05-16 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 On May 16, 2018, Trevena, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) in Chesterbrook, Pennsylvania. 5.07 In connection with the Annual Meeting, there were 66,951,441 shares outstanding as of the March 20, 2018 record date, of which 46,494,760 shares, or approximately 69.44%, were present or represented by proxy at the Annual Meeting. | a18-13855_18k.htm |
| 2018-05-03 | 8-K | 2018-05-03 | 2.02 Results of Operations and Financial Condition | 2.02 The information under this caption and contained in the press release attached hereto as Exhibit 99.1 is furnished by Trevena, Inc. (the “Company”) in accordance with Securities Exchange Commission Release No. 33-8216. | a18-12663_18k.htm |
| 2018-04-12 | 8-K | 2018-04-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On April 9, 2018, Roberto Cuca, Senior Vice President and Chief Financial Officer of Trevena, Inc. (the “Company”) formally notified the Company of his resignation, effective as of May 3, 2018. | a18-9962_18k.htm |
| 2018-04-06 | 8-K | 2018-04-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 4, 2018, Maxine Gowen, Ph.D., President, Chief Executive Officer and director of Trevena, Inc. (the “Company”) formally notified the Company’s Board of Directors (the “Board”) of her intention to retire as an employee from the Company, effective as of October 1, 2018. | a18-9654_18k.htm |
| 2018-03-07 | 8-K | 2018-03-07 | 2.02 Results of Operations and Financial Condition | 2.02 The information under this caption and contained in the press release attached hereto as Exhibit 99.1 is furnished by Trevena, Inc. (the “Company”) in accordance with Securities Exchange Commission Release No. 33-8216. | a18-7415_28k.htm |
| 2018-03-02 | 8-K | 2018-02-28 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 5.02 On February 28, 2018, the Board (i) approved a cash incentive award for fiscal year 2017 under the Trevena, Inc. Incentive Compensation Plan (the “ICP”) to be made to Maxine Gowen, Ph.D., the President and Chief Executive Officer (the “CEO”) of the Company, and (ii) ratified ICP cash incentive awards for fiscal year 2017 that were approved by the Compensation Committee of the Board for the Company’s executive officers other than the CEO. | a18-7415_18k.htm |
| 2018-02-02 | 8-K | 2018-01-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (c) On February 2, 2018, Trevena, Inc. (“Trevena” or the “Company”) announced the appointment of Carrie L. Bourdow, 55, to the position of Executive Vice President and Chief Operating Officer, effective immediately. | a18-5236_18k.htm |
| 2018-01-05 | 8-K | 2018-01-02 | 8.01 Other Events | 8.01 On January 2, 2018, Trevena, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for OLINVO™ (oliceridine) Injection. | a18-2295_18k.htm |